Catalent Inc (CTLT) Receives $28.50 Average Target Price from Brokerages
Shares of Catalent Inc (NASDAQ:CTLT) have been given an average rating of “Buy” by the ten ratings firms that are covering the firm. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $28.50.
A number of equities analysts have commented on the stock. Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, November 11th. TheStreet cut shares of Catalent from a “hold” rating to a “sell” rating in a research note on Monday, November 7th. Jefferies Group LLC reissued a “hold” rating and issued a $28.00 price objective on shares of Catalent in a research note on Tuesday, November 8th. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on shares of Catalent in a research note on Thursday, December 1st. They issued a “neutral” rating and a $25.00 price objective for the company.
“Catalent Inc (CTLT) Receives $28.50 Average Target Price from Brokerages” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this report can be accessed at http://www.watchlistnews.com/catalent-inc-ctlt-receives-28-50-average-target-price-from-brokerages/1121595.html.
In other Catalent news, Director Donald E. Morel, Jr. acquired 10,000 shares of the company’s stock in a transaction on Wednesday, February 15th. The stock was acquired at an average cost of $29.27 per share, with a total value of $292,700.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.
Institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. boosted its position in shares of Catalent by 62.6% in the third quarter. PNC Financial Services Group Inc. now owns 3,908 shares of the company’s stock worth $101,000 after buying an additional 1,504 shares during the last quarter. Emerald Acquisition Ltd. purchased a new stake in Catalent during the second quarter valued at about $123,000. Advisor Group Inc. raised its stake in Catalent by 93.9% in the third quarter. Advisor Group Inc. now owns 5,277 shares of the company’s stock valued at $134,000 after buying an additional 2,556 shares during the period. Bronfman E.L. Rothschild L.P. raised its stake in Catalent by 7.6% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 5,673 shares of the company’s stock valued at $147,000 after buying an additional 400 shares during the period. Finally, Integrated Investment Consultants LLC purchased a new stake in Catalent during the third quarter valued at about $165,000.
Catalent (NASDAQ:CTLT) opened at 28.91 on Tuesday. The company’s 50 day moving average is $27.28 and its 200 day moving average is $25.50. The stock has a market cap of $3.61 billion and a PE ratio of 40.21. Catalent has a 12 month low of $20.94 and a 12 month high of $32.24.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings data on Monday, February 6th. The company reported $0.27 EPS for the quarter, hitting analysts’ consensus estimates of $0.27. The business earned $483.70 million during the quarter, compared to analysts’ expectations of $474.07 million. During the same period in the previous year, the business earned $0.36 earnings per share. The business’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts anticipate that Catalent will post $1.38 EPS for the current fiscal year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.